Related Experiment Video
Updated: May 22, 2026
10:13
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
Caffeic Acid and Its Derivatives as Potential Therapies for Neurological Disorders
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Current Neuropharmacology
|May 21, 2026
Summary
Caffeic acid and its derivatives show promise in combating neuroinflammation, a key factor in neurological disorders. These compounds offer potential therapeutic benefits for conditions involving brain inflammation and damage.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Neuroinflammation significantly hinders post-injury recovery and contributes to neurological disorders.
- The interplay between inflammation and redox imbalance is central to the pathogenesis of many neurological conditions.
- Caffeic acid derivatives have demonstrated significant neuroprotective potential.
Purpose of the Study:
- To review the neuroprotective effects of caffeic acid and its derivatives against CNS diseases involving neuroinflammation.
- To highlight the therapeutic potential of these compounds for neurological and neurodegenerative disorders.
Main Methods:
- Literature review of studies investigating caffeic acid and its derivatives.
- Analysis of in vitro and in vivo models of neuroinflammation.
- Examination of effects on conditions like cognitive impairment, LPS-induced neuroinflammation, amyloid-tau neuroinflammation, brain trauma, spinal cord injury, and chemobrain.
Main Results:
- Caffeic acid exhibits neuroprotection against cognitive impairment and specific neuroinflammatory models.
- Caffeic acid phenethyl ester demonstrates protective effects in models of brain trauma, spinal cord injury, and ischemic attacks.
- Ferulic acid, chlorogenic acid, danshensu, and chicoric acid also show neuroprotective activities in various models.
Conclusions:
- Caffeic acid and its derivatives effectively mitigate the adverse effects of neuroinflammation.
- These compounds represent promising therapeutic agents for a range of neurological and neurodegenerative disorders.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...